Posted on

Baby Pibu’s™ Baby Sunscreen SPF 30+ Achieves The Skin Cancer Foundation’s Daily Use Seal of Recommendation

SCF_Seal-Daily_pantone

What Does It Mean to Achieve The Skin Cancer Foundation Daily Use Seal of Recommendation?

Per The Skin Cancer Foundation’s website:  “To earn the Seal of Recommendation, a manufacturer must provide scientific data showing that its product sufficiently and safely ‘aids in the prevention of sun-induced damage to the skin.’ The data are reviewed by a volunteer committee of photo biologists – experts in the study of the interaction between ultraviolet radiation and the skin.”

 The Skin Cancer Foundation’s Daily Use Seal of Recommendation is difficult to attain. They have stringent requirements including clinical testing.  They also have a panel of photobiologists that place the product under additional scrutiny to ensure it protects against exposure to the sun as it claims.

The Skin Cancer Foundation’s requirements for sunscreens to achieve their recommendation include:

  •  UVB protection: A sun protection factor (SPF) of 15 or higher. Validation of the SPF number by testing on 10 human subjects.
  • UVA Protection: A critical wavelength of 370.
  • Acceptable results for phototoxic reactions and contact irritancy testing on 20 human subjects.
  • Testing data for any claims that a sunscreen is water- or sweat-resistant.

You can learn more about The Skin Cancer Foundation’s testing criteria on their website, www.skincancer.org.

At Baby Pibu™ we test and select only the safest ingredients for our products.  Though not required by the FDA for personal care products, each and every Baby Pibu™ product has been through extensive examination by panels of board-certified dermatologists.  We are proud that The Skin Cancer Foundation has found Baby Pibu’s™ Baby Sunscreen SPF 30+ worthy of their seal of recommendation.

Here are some important notes for consideration when choosing products:

What does it mean to be clinically tested?

Personal care or cosmetic products that claim to be clinically tested have gone through the rigor of additional examination through clinical testing at regulated research laboratories in the USA. These laboratories have a panel of investigators including board-certified dermatologists.  Tests that are performed include patch testing, cumulative irritation testing, and phototoxicity testing. All of these tests follow a standard protocol approved by the Institutional Review Board (IRB).

Patch testing is a test that follows a product over six weeks to determine whether or not it is causing any allergic reactions.  Baby Pibu™ products were put through this testing and were found to be non-sensitizing (non-allergic) and non-irritating.

Cumulative irritation testing is a test that runs for a two-week time period. In this test, products are examined to see if they cause cumulative dermal (skin) irritation or not. Baby Pibu™ products were found to cause no significant cumulative dermal irritation.

Phototoxicity testing is a test that determines whether or not a product causes a phototoxic response, meaning the product could facilitate sunburn when someone spends time in the sun. Baby Pibu™ products were not found to cause a dermal phototoxic response.

Baby Pibu™ products underwent patch, cumulative irritation and photoxicity testing and were found non-irritating, non-sensitizing and had no phototoxic response.

For more information on The Skin Cancer Foundation and its Seal of Recommendation, visit The Skin Cancer Foundation website at www.skincancer.org.

— The Baby Pibu™ Team

Share

Leave a Reply

Your email address will not be published. Required fields are marked *